Frontiers in Anti-Cancer Drug Discovery

Volume 10

by

Atta-ur-Rahman , M. Iqbal Choudhary

DOI: 10.2174/97898114007111191001
eISBN: 978-981-14-0071-1, 2019
ISBN: 978-981-14-0191-6
ISSN: 2451-8395 (Print)
ISSN: 1879-6656 (Online)





Frontiers in Anti-Cancer Drug Discovery is a book series devoted to publishing the latest advances in anti-cancer drug design and disc...[view complete introduction]
US $
Buy Personal eBook
89
Order Library eBook
356
Order Printed Copy
*107
Order PDF + Printed Copy (Special Offer)
*151

*(Excluding Mailing and Handling)

🔒Secure Checkout Personal information is secured with SSL technology

The Emerging Role of Monocarboxylate Transporter-1 in Cancer: Overview and Therapeutic Opportunities

- Pp. 23-42 (20)

Gouthami Thumma, Kiran Gangarapu, Anvesh Jallapally and Anil Kumar Mondru

Abstract

Cancer has become a global pandemic that accounts for almost 13% more deaths than any other infectious diseases. According to the World Health Organization (WHO), projections of cancer prevalence is expected to raise to 21.7 million cases and 13 million deaths by 2030. Over the last 10 years, considerable improvements have been achieved in the management of cancer, and yet the disease remains incurable. There is an urgent need to develop therapeutic agents with novel drug combinations to achieve better efficacy, and reduce the possibility of relapse and drug resistance. Cancer progression, development of metastases represents the major characteristic feature for solid tumours in the presence of hypoxia. Under hypoxic conditions, cancer cells consume glucose that is metabolized to lactate, and then exported into the extracellular milieu, contributing to the acidic microenvironment. In this context, monocarboxylate transporters (MCTs) will play a significant role in maintaining the hyper-glycolytic acid resistant phenotype of cancer, allowing the maintenance of the high glycolytic rates by performing lactate efflux, and pH regulation by the cotransport of protons. Hence, MCTs constitute attractive adjuvant targets for cancer therapy. In this chapter, we review cancer biology from the perspective of the lactate shuttle concept which mainly focuses on the development of MCT inhibitors and highlights current and potential future therapeutic approaches that supports the notion of targeting lactate metabolism with novel anticancer agents.

Purchase Chapter  Book Details

Advertisement


Webmaster Contact: info@benthamscience.net Copyright © 2019 Bentham Science